# 510(k) SUMMARY

This summary of 510(k) safety and effectiveness information is supplied in accordance with the requirements of the SMDA of 1990 and 21 CFR 807.92

The assigned 510(k) number is K083130.

Date: July 6, 2009

# Submitted by:

Wallac Oy - PerkinElmer Inc. Mustionkatu 6 20750 Turku, Finland

Contact person: Primary:

Kay A. Taylor Tele: 317-418-1735 Fax: 317-536-3064

Secondary:

Raija Koskivaara Tele: +358-2-2678 111 Fax: +358-2-2678 357

# Trade Name:

NeoBase Non-derivatized MSMS Kit

# Common Name:

NeoBase kit or Non-derivatized kit

# Classification Name:

Newborn screening test system for amino acids, free carnitine, and acylcarnitines using tandem mass spectrometry (21 CFR $\ S$ 862.1055 /Product code NQL)

Predicate device(s):

NeoGram Amino Acids and Acylcarnitines Tandem Mass Spectrometry Kit, K031878

# Device description:

The measurement of amino acids, succinylacetone, free carnitine, and acylcarnitines with the NeoBase assay involves extraction of dried blood spots from newborns with a solution containing stable-isotope labeled internal standards and analysis using a tandem mass spectrometry (MsMs) system. The response of each analyte relative to their corresponding stable-isotope labeled internal standard is proportional to analyte concentration

# Intended Use:

The NeoBase Non-derivatized MSMs reagent kit is intended for the measurement and evaluation of amino acids, succinylacetone, free carnitine, and acylcarnitine concentrations from newborn heel prick blood samples dried on filter paper. Quantitative analysis of these analytes (Tabel 1) and their relationship with each other is intended to provide analyte concentration profiles that may aid in screening newborns for metabolic disorders.

# Instruments:

PerkinElmer MS2 Tandem Mass Spectrometer System and, - PerkinEImer MS/Ms Qmicro Screening System

Table 1. Analytes measured by the NeoBase Non-derivatized MSMS Kit.   

<table><tr><td colspan="1" rowspan="1">ANALYTE NAME</td><td colspan="1" rowspan="1">ABBREVIATION</td></tr><tr><td colspan="2" rowspan="1">Amino acids</td></tr><tr><td colspan="1" rowspan="1">Alanine</td><td colspan="1" rowspan="1">Ala</td></tr><tr><td colspan="1" rowspan="1">Arginine</td><td colspan="1" rowspan="1">Arg</td></tr><tr><td colspan="1" rowspan="1">Citrulline</td><td colspan="1" rowspan="1">Cit</td></tr><tr><td colspan="1" rowspan="1">Glycine</td><td colspan="1" rowspan="1">Gly</td></tr><tr><td colspan="1" rowspan="1">Leucine/Isoleucine/Hydroxyproline*</td><td colspan="1" rowspan="1">Leu/lle/Pro-OH</td></tr><tr><td colspan="1" rowspan="1">Methionine</td><td colspan="1" rowspan="1">Met</td></tr><tr><td colspan="1" rowspan="1">Ornithine</td><td colspan="1" rowspan="1">Orn</td></tr><tr><td colspan="1" rowspan="1">Phenylalanine</td><td colspan="1" rowspan="1">Phe</td></tr><tr><td colspan="1" rowspan="1">Proline</td><td colspan="1" rowspan="1">Pro</td></tr><tr><td colspan="1" rowspan="1">Tyrosine</td><td colspan="1" rowspan="1">Tyr</td></tr><tr><td colspan="1" rowspan="1">Valine</td><td colspan="1" rowspan="1">Val</td></tr><tr><td colspan="2" rowspan="1">Carnitines</td></tr><tr><td colspan="1" rowspan="1">Free carnitine</td><td colspan="1" rowspan="1">CO</td></tr><tr><td colspan="1" rowspan="1">Acetylcarnitine</td><td colspan="1" rowspan="1">C2</td></tr><tr><td colspan="1" rowspan="1">Propionylcarnitine</td><td colspan="1" rowspan="1">C3</td></tr><tr><td colspan="1" rowspan="1">Malonylcarnitine / 3-Hydroxy-butyrylcarnitine*</td><td colspan="1" rowspan="1">C3DC/C4OH</td></tr><tr><td colspan="1" rowspan="1">Butyrylcarnitine</td><td colspan="1" rowspan="1">C4</td></tr><tr><td colspan="1" rowspan="1">Methylmalonyl / 3-Hydroxy-isovalerylcarnitine*</td><td colspan="1" rowspan="1">C4DC/C5OH</td></tr><tr><td colspan="1" rowspan="1">Isovalerylcarnitine</td><td colspan="1" rowspan="1">C5</td></tr><tr><td colspan="1" rowspan="1">Tiglylcarnitine</td><td colspan="1" rowspan="1">C5:1</td></tr><tr><td colspan="1" rowspan="1">Glutarylcarnitine / 3-Hydroxy-hexanoylcarnitine*</td><td colspan="1" rowspan="1">C5DC/C6OH</td></tr><tr><td colspan="1" rowspan="1">Hexanoylcarnitine</td><td colspan="1" rowspan="1">C6</td></tr><tr><td colspan="1" rowspan="1">Adipylcarnitine</td><td colspan="1" rowspan="1">C6DC</td></tr><tr><td colspan="1" rowspan="1">Octanoylcarnitine</td><td colspan="1" rowspan="1">C8</td></tr><tr><td colspan="1" rowspan="1">Octenoylcarnitine</td><td colspan="1" rowspan="1">C8:1</td></tr><tr><td colspan="1" rowspan="1">Decanoylcarnitine</td><td colspan="1" rowspan="1">C10</td></tr><tr><td colspan="1" rowspan="1">Decenoylcarnitine</td><td colspan="1" rowspan="1">C10:1</td></tr><tr><td colspan="1" rowspan="1">DecadienoyIcarnitine</td><td colspan="1" rowspan="1">C10:2</td></tr><tr><td colspan="1" rowspan="1">DodecanoyIcarnitine</td><td colspan="1" rowspan="1">C12</td></tr><tr><td colspan="1" rowspan="1">ANALYTE NAME</td><td colspan="1" rowspan="1">ABBREVIATION</td></tr><tr><td colspan="2" rowspan="1">Carnitines</td></tr><tr><td colspan="1" rowspan="1">Dodecenoylcarnitine</td><td colspan="1" rowspan="1">C12:1</td></tr><tr><td colspan="1" rowspan="1">Tetradecanoylcarnitine (Myristoylcarnitine)</td><td colspan="1" rowspan="1">C14</td></tr><tr><td colspan="1" rowspan="1">Tetradecenoylcarnitine</td><td colspan="1" rowspan="1">C14:1</td></tr><tr><td colspan="1" rowspan="1">Tetradecadienoylcarnitine</td><td colspan="1" rowspan="1">C14:2</td></tr><tr><td colspan="1" rowspan="1">3-Hydroxy-tetradecanoylcarnitine</td><td colspan="1" rowspan="1">C140H</td></tr><tr><td colspan="1" rowspan="1">Hexadecanoylcarnitine (palmitoylcarnitine)</td><td colspan="1" rowspan="1">C16</td></tr><tr><td colspan="1" rowspan="1">Hexadecenoylcarnitine</td><td colspan="1" rowspan="1">C16:1</td></tr><tr><td colspan="1" rowspan="1">3-Hydroxy-hexadecanoylcarnitine</td><td colspan="1" rowspan="1">C160H</td></tr><tr><td colspan="1" rowspan="1">3-Hydroxy-hexadecenoylcarnitine</td><td colspan="1" rowspan="1">C16:10H</td></tr><tr><td colspan="1" rowspan="1">Octadecanoylcarnitine (Stearoylcarnitine)</td><td colspan="1" rowspan="1">C18</td></tr><tr><td colspan="1" rowspan="1">Octadecenoylcarnitine (Oleylcarnitine)</td><td colspan="1" rowspan="1">C18:1</td></tr><tr><td colspan="1" rowspan="1">Octadecadienoylcarnitine (Linoleylcarnitine)</td><td colspan="1" rowspan="1">C18:2</td></tr><tr><td colspan="1" rowspan="1">3-Hydroxy-octadecanoylcarnitine</td><td colspan="1" rowspan="1">C180H</td></tr><tr><td colspan="1" rowspan="1">3-Hydroxy-octadecenoylcarnitine</td><td colspan="1" rowspan="1">C18:10H</td></tr><tr><td colspan="2" rowspan="1">Ketones</td></tr><tr><td colspan="1" rowspan="1">Succinylacetone</td><td colspan="1" rowspan="1">SA</td></tr></table>

\*Analytes in these rows are either isomers or isobars and cannot be distinguished in the tandem mass spectrometry experiment.

# Device Comparison:

able 5.1: Comparison of the NeoBase Non-derivatized MSMS and predicate device   

<table><tr><td colspan="3" rowspan="1">GENERAL CHARACTERISTICS</td></tr><tr><td colspan="1" rowspan="1">Parameter</td><td colspan="1" rowspan="1">NeoBase Non-derivatized MsMs kit</td><td colspan="1" rowspan="1">Predicate Device</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">The NeoBase Non-derivatized MSMSreagent kit is intended for themeasurement and evaluation of aminoacids, succinylacetone, free carnitine,and acylcarnitine concentrations fromnewborn heel prick blood samples driedon filter paper. Quantitative analysis ofthese analytes (Table 1) and theirrelationship with each other is intendedto provide analyte concentration profilesthat may aid in screening newborns formetabolic disorders.[intended use employs a table toidentify each analyte detected]</td><td colspan="1" rowspan="1">The NeoGram Amino Acids andAcylcarnitines Tandem MassSpectrometry kit is intended for themeasurement and evaluation ofamino acids, free carnitine, andacylcarnitine concentrations fromnewborn heel prick blood samplesdried on filter paper. Table 1 detailsthe analytes measured by the kitQuantitative analysis of aminoacids, free carnitine, andacylcarnitine and their relationshipwith each other is intended toprovide analyte concentrationprofiles that may aid in screeningnewborns for one or more ofseveral metabolic disorders. Thiskit is to be used for in vitro</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">diagnostic use only, by trained,qualified laboratory personnel.[intended use employs a table toidentify each analyte detected]</td></tr><tr><td colspan="1" rowspan="1">Disorders Screened</td><td colspan="1" rowspan="1">Amino-, organic-, and fatty acidmetabolic disorders</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Analytes Measured</td><td colspan="1" rowspan="1">Amino acids, free carnitine,acylcarnitines, and succinylacetone</td><td colspan="1" rowspan="1">Amino acids, free carnitine, andacylcarnitines</td></tr><tr><td colspan="1" rowspan="1">Methodology</td><td colspan="1" rowspan="1">Microplate based tandem massspectrometric assay</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Test Principle</td><td colspan="1" rowspan="1">Amino acids and carnitines in sampleare measured by tandem massspectrometry through analyte-specificmass transitions appropriate for eachtype of analyte. The extracted analytesare measured for set time periods andcompared to the signal intensitiesproduced by the corresponding isotope-labeled internal standards. Theconcentrations are determined bycomparing the signal intensities of theknown standards to the measuredanalytes.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Quantitative Nature</td><td colspan="1" rowspan="1">Quantitative by internal standardization</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Requirements</td><td colspan="1" rowspan="1">Newborn blood collected on Schleicherand Schuell 903 filter paper per NCCLSstandards</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Throughput</td><td colspan="1" rowspan="1">Ninety-six tests per microtiter plate:Multiple plates can be analyzed</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Analysis Time</td><td colspan="1" rowspan="1">2 to 2.5 hours per plate.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Controls1</td><td colspan="1" rowspan="1">Controls are blood spots fromprocessed human blood enriched withseveral amino acids, carnitines andsuccinylacetone.</td><td colspan="1" rowspan="1">Controls are blood spots fromprocessed human blood enrichedwith several amino acids andcarnitines.</td></tr><tr><td colspan="1" rowspan="1">Calibrators</td><td colspan="1" rowspan="1">Internal calibration using severalisotopically labeled standards, includedas dried material in vials. Internalstandards must be reconstituted withextraction solution prior to their use.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Assay format</td><td colspan="1" rowspan="1">Non-derivatized (analytes measured intheir native forms)</td><td colspan="1" rowspan="1">Derivatized (analytes converted tobutyl esters prior to beingmeasured)</td></tr></table>

# Analytes measured by the device

Table 5.2: Analytes measured by the NeoBase kit and their most common abbreviated names   

<table><tr><td rowspan=1 colspan=1>ANALYTE NAME</td><td rowspan=1 colspan=1>ABBREVIATION</td></tr><tr><td rowspan=1 colspan=2>Amino acids</td></tr><tr><td rowspan=1 colspan=1>Alanine</td><td rowspan=1 colspan=1>Ala</td></tr><tr><td rowspan=1 colspan=1>Arginine</td><td rowspan=1 colspan=1>Arg</td></tr><tr><td rowspan=1 colspan=1>Citrulline</td><td rowspan=1 colspan=1>Cit</td></tr><tr><td rowspan=1 colspan=1>Glycine</td><td rowspan=1 colspan=1>Gly</td></tr></table>

Table 5.2: Analytes measured by the NeoBase kit and their most common abbreviated names (continued)   

<table><tr><td rowspan=1 colspan=1>Leucine/Isoleucine/Hydroxyproline*</td><td rowspan=1 colspan=1>Leu/lle/Pro-OH</td></tr><tr><td rowspan=1 colspan=1>Methionine</td><td rowspan=1 colspan=1>Met</td></tr><tr><td rowspan=1 colspan=1>Ornithine</td><td rowspan=1 colspan=1>Orn</td></tr><tr><td rowspan=1 colspan=1>Phenylalanine</td><td rowspan=1 colspan=1>Phe</td></tr><tr><td rowspan=1 colspan=1>Proline</td><td rowspan=1 colspan=1>Pro</td></tr><tr><td rowspan=1 colspan=1>Tyrosine</td><td rowspan=1 colspan=1>Tyr</td></tr><tr><td rowspan=1 colspan=1>Valine</td><td rowspan=1 colspan=1>Val</td></tr><tr><td rowspan=1 colspan=2>Carnitines</td></tr><tr><td rowspan=1 colspan=1>Free carnitine</td><td rowspan=1 colspan=1>CO</td></tr><tr><td rowspan=1 colspan=1>Acetylcarnitine</td><td rowspan=1 colspan=1>C2</td></tr><tr><td rowspan=1 colspan=1>PropionyIcarnitine</td><td rowspan=1 colspan=1>C3</td></tr><tr><td rowspan=1 colspan=1>Malonylcarnitine / 3-Hydroxy-butyrylcarnitine&quot;</td><td rowspan=1 colspan=1>C3DC/C4OH</td></tr><tr><td rowspan=1 colspan=1>Butyrylcarnitine</td><td rowspan=1 colspan=1>C4</td></tr><tr><td rowspan=1 colspan=1>Methylmalonyl / 3-Hydroxy-isovalerylcarnitine*</td><td rowspan=1 colspan=1>C4DC/C5OH</td></tr><tr><td rowspan=1 colspan=1>Isovalerylcarnitine</td><td rowspan=1 colspan=1>C5</td></tr><tr><td rowspan=1 colspan=1>Tiglylcarnitine</td><td rowspan=1 colspan=1>C5:1</td></tr><tr><td rowspan=1 colspan=1>Glutarylcarnitine / 3-Hydroxy-hexanoylcarnitine*</td><td rowspan=1 colspan=1>C5DC/C60H</td></tr><tr><td rowspan=1 colspan=1>Hexanoylcarnitine</td><td rowspan=1 colspan=1>C6</td></tr><tr><td rowspan=1 colspan=1>Adipylcarnitine</td><td rowspan=1 colspan=1>C6DC</td></tr><tr><td rowspan=1 colspan=1>OctanoyIcarnitine</td><td rowspan=1 colspan=1>C8</td></tr><tr><td rowspan=1 colspan=1>Octenoylcarnitine</td><td rowspan=1 colspan=1>C8:1</td></tr><tr><td rowspan=1 colspan=1>Decanoylcarnitine</td><td rowspan=1 colspan=1>C10</td></tr><tr><td rowspan=1 colspan=1>Decenoylcarnitine</td><td rowspan=1 colspan=1>C10:1</td></tr><tr><td rowspan=1 colspan=1>Decadienoylcarnitine</td><td rowspan=1 colspan=1>C10:2</td></tr><tr><td rowspan=1 colspan=1>Dodecanoylcarnitine</td><td rowspan=1 colspan=1>C12</td></tr><tr><td rowspan=1 colspan=1>Dodecenoylcarnitine</td><td rowspan=1 colspan=1>C12:1</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Tetradecanoylcarnitine (Myristoylcarnitine)</td><td rowspan=1 colspan=1>C14</td></tr><tr><td rowspan=1 colspan=1>Tetradecenoylcarnitine</td><td rowspan=1 colspan=1>C14:1</td></tr><tr><td rowspan=1 colspan=1>Tetradecadienoylcarnitine</td><td rowspan=1 colspan=1>C14:2</td></tr><tr><td rowspan=1 colspan=1>3-Hydroxy-tetradecanoylcarnitine</td><td rowspan=1 colspan=1>C140H</td></tr><tr><td rowspan=1 colspan=1>Hexadecanoylcarnitine (palmitoylcarnitine)</td><td rowspan=1 colspan=1>C16</td></tr><tr><td rowspan=1 colspan=1>Hexadecenoylcarnitine</td><td rowspan=1 colspan=1>C16:1</td></tr><tr><td rowspan=1 colspan=1>3-Hydroxy-hexadecanoylcarnitine</td><td rowspan=1 colspan=1>C16OH</td></tr><tr><td rowspan=1 colspan=1>3-Hydroxy-hexadecenoylcarnitine</td><td rowspan=1 colspan=1>C16:10H</td></tr><tr><td rowspan=1 colspan=1>Octadecanoylcarnitine (Stearoylcarnitine)</td><td rowspan=1 colspan=1>C18</td></tr><tr><td rowspan=1 colspan=1>Octadecenoylcarnitine (Oleylcarnitine)</td><td rowspan=1 colspan=1>C18:1</td></tr><tr><td rowspan=1 colspan=1>Octadecadienoylcarnitine (Linoleylcarnitine)</td><td rowspan=1 colspan=1>C18:2</td></tr><tr><td rowspan=1 colspan=1>3-Hydroxy-octadecanoylcarnitine</td><td rowspan=1 colspan=1>C180H</td></tr><tr><td rowspan=1 colspan=1>3-Hydroxy-octadecenoylcarnitine</td><td rowspan=1 colspan=1>C18:10H</td></tr><tr><td rowspan=1 colspan=2>Ketones</td></tr><tr><td rowspan=1 colspan=2>Succinylacetone                                                                     SA or SUAC</td></tr></table>

Analytes in these rows are either isomers or isobars and cannot be distinguished in the tandem mass spectrometry experiment.

# Substantial equivalency:

# (1) Non-clinical

The NeoBase Non-derivatized MSMs kit was compared to the predicate NeoGram Amino Acids and Acylcarnitines Tandem Mass Spectrometry Kit, k031878. Both devices utilize tandem mass spectrometry to measure a panel of amino acids and acylcarnitines from neonatal dried blood spots. The panel of analytes measured by both devices is the same with the main exception that the NeoBase kit also includes the measurement of succinylacetone (the primary marker for the screening of Tyrosinemia Type I). Analytically, both devices are also very similar with the exception that the NeoBase kit does not require the derivatization of the sample prior to measurement (Tables 5.1 and 5.2).

The established performance characteristics of the NeoBase kit were compared against the corresponding characteristics reported in the predicate device product insert. A summary of the performance characteristics is presented in Tables 5.3 to 5.6. Both kits provide equivalent precision and recoveries and both devices have measurable ranges that cover all clinically significant ranges. Therefore, both kits provide performance levels that are adequate for their intended use.

# Precision

# Table 5.3: Averaged Total imprecision for amino acids. Data shown are average Total imprecision coefficients of variation $( \% C V )$ for both assays.

<table><tr><td rowspan=1 colspan=1>Assay</td><td rowspan=1 colspan=1> AALA</td><td rowspan=1 colspan=1>ARG</td><td rowspan=1 colspan=1>CIT</td><td rowspan=1 colspan=1>GLY</td><td rowspan=1 colspan=1>LE</td><td rowspan=1 colspan=1>MET</td><td rowspan=1 colspan=1>ON</td><td rowspan=1 colspan=1>PHE</td><td rowspan=1 colspan=1>MTYR</td><td rowspan=1 colspan=1>VAL</td></tr><tr><td rowspan=1 colspan=1>NeoBase</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>Predicate</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>14</td></tr></table>

Table 5.4: Averaged Total imprecision for carnitine and acylcarnitines. Data shown are average Total imprecision coefficients of variation $( \% C V )$ for both assays.   

<table><tr><td rowspan=1 colspan=1>Assay</td><td rowspan=1 colspan=1>CO</td><td rowspan=1 colspan=1>T 2</td><td rowspan=1 colspan=1>C3</td><td rowspan=1 colspan=1>C4</td><td rowspan=1 colspan=1>C5</td><td rowspan=1 colspan=1>C5DC</td><td rowspan=1 colspan=1> </td><td rowspan=1 colspan=1>C8</td><td rowspan=1 colspan=1>*C10</td><td rowspan=1 colspan=1>C12</td><td rowspan=1 colspan=1>C14</td><td rowspan=1 colspan=1>C16</td><td rowspan=1 colspan=1>C18</td></tr><tr><td rowspan=1 colspan=1>NeoBase</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>Predicate</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>9</td></tr></table>

# Recovery

Table 5.5: Averaged analyte percent recovery for both assays and associated %CV   

<table><tr><td colspan="1" rowspan="1"></td><td colspan="2" rowspan="1">NeoBase Recovery</td><td colspan="2" rowspan="1">Predicate Recovery</td></tr><tr><td colspan="1" rowspan="1">Analyte</td><td colspan="1" rowspan="1">Average%</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">Average%</td><td colspan="1" rowspan="1">%CV</td></tr><tr><td colspan="1" rowspan="1">ALA</td><td colspan="1" rowspan="1">101</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">71</td><td colspan="1" rowspan="1">11</td></tr><tr><td colspan="1" rowspan="1">ARG</td><td colspan="1" rowspan="1">94</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">91</td><td colspan="1" rowspan="1">12</td></tr><tr><td colspan="1" rowspan="1">CIT</td><td colspan="1" rowspan="1">101</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">93</td><td colspan="1" rowspan="1">9</td></tr><tr><td colspan="1" rowspan="1">GLY</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">87</td><td colspan="1" rowspan="1">s11</td></tr><tr><td colspan="1" rowspan="1">LEU</td><td colspan="1" rowspan="1">97</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">69</td><td colspan="1" rowspan="1">9</td></tr><tr><td colspan="1" rowspan="1">MET</td><td colspan="1" rowspan="1">89</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">89</td><td colspan="1" rowspan="1">18</td></tr><tr><td colspan="1" rowspan="1">ORN</td><td colspan="1" rowspan="1">91</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">72</td><td colspan="1" rowspan="1">14</td></tr><tr><td colspan="1" rowspan="1">PHE</td><td colspan="1" rowspan="1">99</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">96</td><td colspan="1" rowspan="1">22</td></tr><tr><td colspan="1" rowspan="1">TYR</td><td colspan="1" rowspan="1">101</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">81</td><td colspan="1" rowspan="1">11</td></tr><tr><td colspan="1" rowspan="1">VAL</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">68</td><td colspan="1" rowspan="1">16</td></tr><tr><td colspan="1" rowspan="1">CO</td><td colspan="1" rowspan="1">93</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">139</td><td colspan="1" rowspan="1">12</td></tr><tr><td colspan="1" rowspan="1">C2</td><td colspan="1" rowspan="1">97</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">67</td><td colspan="1" rowspan="1">23</td></tr><tr><td colspan="1" rowspan="1">C3</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">97</td><td colspan="1" rowspan="1">19</td></tr><tr><td colspan="1" rowspan="1">C4</td><td colspan="1" rowspan="1">94</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">104</td><td colspan="1" rowspan="1">11</td></tr><tr><td colspan="1" rowspan="1">C5</td><td colspan="1" rowspan="1">98</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">111</td><td colspan="1" rowspan="1">7</td></tr><tr><td colspan="1" rowspan="1">C5DC</td><td colspan="1" rowspan="1">102</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">102</td><td colspan="1" rowspan="1">14</td></tr><tr><td colspan="1" rowspan="1">C6</td><td colspan="1" rowspan="1">95</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">89</td><td colspan="1" rowspan="1">10</td></tr><tr><td colspan="1" rowspan="1">C8</td><td colspan="1" rowspan="1">97</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">105</td><td colspan="1" rowspan="1">21</td></tr><tr><td colspan="1" rowspan="1">C10</td><td colspan="1" rowspan="1">101</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">83</td><td colspan="1" rowspan="1">10</td></tr><tr><td colspan="1" rowspan="1">C12</td><td colspan="1" rowspan="1">97</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">106</td><td colspan="1" rowspan="1">33</td></tr><tr><td colspan="1" rowspan="1">C14</td><td colspan="1" rowspan="1">95</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">95</td><td colspan="1" rowspan="1">18</td></tr><tr><td colspan="1" rowspan="1">C16</td><td colspan="1" rowspan="1">93</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">98</td><td colspan="1" rowspan="1">15</td></tr><tr><td colspan="1" rowspan="1">C18</td><td colspan="1" rowspan="1">94</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">89</td><td colspan="1" rowspan="1">18</td></tr></table>

# Measurable Ranges

Table 5.6: Measurable ranges for both assays and corresponding clinically significant ranges (all in uM/L).   
Table 5.6: Measurable ranges for both assays and corresponding clinically significant ranges (all in uM/L). Continued.   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>NeoBase Range</td><td rowspan=1 colspan=2>Predicate Range</td><td rowspan=1 colspan=2>Clinical Ranges</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Lower</td><td rowspan=1 colspan=1>Upper</td><td rowspan=1 colspan=1>Lower</td><td rowspan=1 colspan=1>Upper</td><td rowspan=1 colspan=1>N ormal</td><td rowspan=1 colspan=1>Cutoff</td></tr><tr><td rowspan=1 colspan=1>ALA</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>4109</td><td rowspan=1 colspan=1>4.92</td><td rowspan=1 colspan=1>2868.0</td><td rowspan=1 colspan=1>67 - 492</td><td rowspan=1 colspan=1>975 - 1625</td></tr><tr><td rowspan=1 colspan=1>ARG</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>3754</td><td rowspan=1 colspan=1>0.31</td><td rowspan=1 colspan=1>5469.0</td><td rowspan=1 colspan=1>0 -58</td><td rowspan=1 colspan=1>180 - 300</td></tr><tr><td rowspan=1 colspan=1>CIT</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>1711</td><td rowspan=1 colspan=1>0.53</td><td rowspan=1 colspan=1>2169.2</td><td rowspan=1 colspan=1>0 - 36</td><td rowspan=1 colspan=1>113 - 188</td></tr><tr><td rowspan=1 colspan=1>GLY</td><td rowspan=1 colspan=1>50.4</td><td rowspan=1 colspan=1>4794</td><td rowspan=1 colspan=1>9.81</td><td rowspan=1 colspan=1>4023.3</td><td rowspan=1 colspan=1>238 - 808</td><td rowspan=1 colspan=1>975 - 1625</td></tr><tr><td rowspan=1 colspan=1>LEU</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>2598</td><td rowspan=1 colspan=1>9.06</td><td rowspan=1 colspan=1>3078.0</td><td rowspan=1 colspan=1>26 - 239</td><td rowspan=1 colspan=1>263 - 438</td></tr></table>

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>S  NeoBase Range</td><td rowspan=1 colspan=2>PredicateRange</td><td rowspan=1 colspan=2>Clinical Ranges</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Lower </td><td rowspan=1 colspan=1>Upper</td><td rowspan=1 colspan=1>Lower</td><td rowspan=1 colspan=1>Upper</td><td rowspan=1 colspan=1>Normal</td><td rowspan=1 colspan=1>Cutoff</td></tr><tr><td rowspan=1 colspan=1>MET</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>1192</td><td rowspan=1 colspan=1>8.03</td><td rowspan=1 colspan=1>1476.7</td><td rowspan=1 colspan=1>3 - 59</td><td rowspan=1 colspan=1>120 - 200</td></tr><tr><td rowspan=1 colspan=1>ORN</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>3825</td><td rowspan=1 colspan=1>1.60</td><td rowspan=1 colspan=1>4675.4</td><td rowspan=1 colspan=1>5 -214</td><td rowspan=1 colspan=1>360 - 600</td></tr><tr><td rowspan=1 colspan=1>PHE</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>2395</td><td rowspan=1 colspan=1>0.75</td><td rowspan=1 colspan=1>2906.0</td><td rowspan=1 colspan=1>10 - 130</td><td rowspan=1 colspan=1>225 - 375</td></tr><tr><td rowspan=1 colspan=1>TYR</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>2867</td><td rowspan=1 colspan=1>1.42</td><td rowspan=1 colspan=1>2537.1</td><td rowspan=1 colspan=1>14 - 194</td><td rowspan=1 colspan=1>578 - 963</td></tr><tr><td rowspan=1 colspan=1>VAL</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>2388</td><td rowspan=1 colspan=1>114.80</td><td rowspan=1 colspan=1>2900.0</td><td rowspan=1 colspan=1>34 - 213</td><td rowspan=1 colspan=1>300 - 500</td></tr><tr><td rowspan=1 colspan=1>COMSD</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>2298</td><td rowspan=1 colspan=1>2.13</td><td rowspan=1 colspan=1>4143.0</td><td rowspan=1 colspan=1>6.6 - 70.6</td><td rowspan=1 colspan=1>90 - 150</td></tr><tr><td rowspan=1 colspan=1> C2CURUR</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>732</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>166.3</td><td rowspan=1 colspan=1>6.2 - 44.3</td><td rowspan=1 colspan=1>128 - 213</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>130.7</td><td rowspan=1 colspan=1>0 -4.9</td><td rowspan=1 colspan=1>9.75 - 16.25</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>59.61</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>58.4</td><td rowspan=1 colspan=1>0 - 0.92</td><td rowspan=1 colspan=1>2.25 - 3.75</td></tr><tr><td rowspan=1 colspan=1>C5</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>58.73</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>101.6</td><td rowspan=1 colspan=1>0 - 0.61</td><td rowspan=1 colspan=1>1.88 - 3.13</td></tr><tr><td rowspan=1 colspan=1>C5DC</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>28.88</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>30.9</td><td rowspan=1 colspan=1>0 - 0.22</td><td rowspan=1 colspan=1>0.6 - 1</td></tr><tr><td rowspan=1 colspan=1>C6</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>61.50</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>38.0</td><td rowspan=1 colspan=1>0 - 0.33</td><td rowspan=1 colspan=1>0.98 - 1.63</td></tr><tr><td rowspan=1 colspan=1>C8</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>35.42</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>48.0</td><td rowspan=1 colspan=1>0 - 0.46</td><td rowspan=1 colspan=1>1.2-2</td></tr><tr><td rowspan=1 colspan=1>C10</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>28.69</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>46.6</td><td rowspan=1 colspan=1>0 - 0.32</td><td rowspan=1 colspan=1>1.35 - 2.25</td></tr><tr><td rowspan=1 colspan=1>C12</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>42.99</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>76.4</td><td rowspan=1 colspan=1>0 - 0.74</td><td rowspan=1 colspan=1>1.88 - 3.13</td></tr><tr><td rowspan=1 colspan=1>C14</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>41.88</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>32.1</td><td rowspan=1 colspan=1>0 - 0.55</td><td rowspan=1 colspan=1>1.5 - 2.5</td></tr><tr><td rowspan=1 colspan=1>C16</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>107.40</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>76.4</td><td rowspan=1 colspan=1>0.08 - 5.78</td><td rowspan=1 colspan=1>11.25 - 18.75</td></tr><tr><td rowspan=1 colspan=1>C18</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>32.19</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>55.9</td><td rowspan=1 colspan=1>0.1 - 1.69</td><td rowspan=1 colspan=1>3 - 5.0</td></tr></table>

# Method Correlation

The method comparison study was executed based on the CLSl EP9-A2 guidelines. Samples were prepared in duplicates and assayed using both the NeoBase and NeoGram kits according to the corresponding kit inserts resulting in total of 158 samples acquired with each method. Each sample was tested twice within the same run within each method. Linear regression analysis provided correlation coefficients (R and R2) as well as slopes (Tables 5.7 to 5.9). The results from this study indicate that the test and predicate method correlated very well.

Table 5.7: Method comparison: Correlation coefficient R and the $R ^ { 2 }$ for all amino acids.   

<table><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>ALA</td><td rowspan=1 colspan=1>ARG</td><td rowspan=1 colspan=1>CIT 8*</td><td rowspan=1 colspan=1>GLY</td><td rowspan=1 colspan=1>LLEU</td><td rowspan=1 colspan=1>MET</td><td rowspan=1 colspan=1>ORN</td><td rowspan=1 colspan=1>PHE</td><td rowspan=1 colspan=1>TYR</td><td rowspan=1 colspan=1>VAL</td></tr><tr><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>0.98</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.95</td><td rowspan=1 colspan=1>0.95</td><td rowspan=1 colspan=1>0.95</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>0.95</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>0.96</td></tr></table>

# Table 5.8: Method comparison: Correlation coefficient R and the $R ^ { 2 }$ for free carnitine and acylcarnitines.

<table><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>O</td><td rowspan=1 colspan=1>C2</td><td rowspan=1 colspan=1>c3</td><td rowspan=1 colspan=1>C4</td><td rowspan=1 colspan=1>C5</td><td rowspan=1 colspan=1>C5DC</td><td rowspan=1 colspan=1>C6</td><td rowspan=1 colspan=1>C:</td><td rowspan=1 colspan=1>C10</td><td rowspan=1 colspan=1>C12</td><td rowspan=1 colspan=1>G14</td><td rowspan=1 colspan=1>C16</td><td rowspan=1 colspan=1>C18</td></tr><tr><td rowspan=1 colspan=1>VORR</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>0.98</td></tr><tr><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>0.95</td><td rowspan=1 colspan=1>0.96</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>0.95</td><td rowspan=1 colspan=1>0.96</td><td rowspan=1 colspan=1>0.96</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>0.96</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.97</td></tr></table>

Table 5.9: Method comparison: Slopes and Intercepts for all amino acids.   

<table><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>ALA</td><td rowspan=1 colspan=1>ARG</td><td rowspan=1 colspan=1>CIT</td><td rowspan=1 colspan=1>CLY</td><td rowspan=1 colspan=1>LEU</td><td rowspan=1 colspan=1>MET</td><td rowspan=1 colspan=1>ORN</td><td rowspan=1 colspan=1>PHE</td><td rowspan=1 colspan=1>TYR</td><td rowspan=1 colspan=1>VAL</td></tr><tr><td rowspan=1 colspan=1>Slope (B)</td><td rowspan=1 colspan=1>1.24</td><td rowspan=1 colspan=1>1.02</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>1.21</td><td rowspan=1 colspan=1>1.04</td><td rowspan=1 colspan=1>0.93</td><td rowspan=1 colspan=1>1.35</td><td rowspan=1 colspan=1>0.90</td><td rowspan=1 colspan=1>1.12</td><td rowspan=1 colspan=1>1.00</td></tr><tr><td rowspan=1 colspan=1>Intercept (A)</td><td rowspan=1 colspan=1>165.70</td><td rowspan=1 colspan=1>-1.00</td><td rowspan=1 colspan=1>1.50</td><td rowspan=1 colspan=1>-5.50</td><td rowspan=1 colspan=1>34.50</td><td rowspan=1 colspan=1>-2.90</td><td rowspan=1 colspan=1>-1.90</td><td rowspan=1 colspan=1>4.30</td><td rowspan=1 colspan=1>-0.40</td><td rowspan=1 colspan=1>9.60</td></tr></table>

Table 5.10: Method comparison: Slopes and Intercepts for free carnitine and acylcarnitines.   

<table><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>CO</td><td rowspan=1 colspan=1>C2 </td><td rowspan=1 colspan=1>C3</td><td rowspan=1 colspan=1>C4</td><td rowspan=1 colspan=1>CS</td><td rowspan=1 colspan=1>C5DC</td><td rowspan=1 colspan=1>CG</td><td rowspan=1 colspan=1>c8</td><td rowspan=1 colspan=1>C16l</td><td rowspan=1 colspan=2>C12MC14</td><td rowspan=1 colspan=1>C16</td><td rowspan=1 colspan=1>C18</td></tr><tr><td rowspan=1 colspan=1>Slope (B)</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>1.19</td><td rowspan=1 colspan=1>1.05</td><td rowspan=1 colspan=1>0.96</td><td rowspan=1 colspan=1>0.76</td><td rowspan=1 colspan=1>0.89</td><td rowspan=1 colspan=1>1.01</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>1.16</td><td rowspan=1 colspan=1>1.02</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>1.03</td><td rowspan=1 colspan=1>0.96</td></tr><tr><td rowspan=1 colspan=1>YNRYIntercept(A)</td><td rowspan=1 colspan=1>3.30</td><td rowspan=1 colspan=1>-7.70</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>0.50</td></tr></table>

# () Clinical CLINICAL CORRELATION STUDIES

The clinical correlation studies took place at two different US newborn screening laboratories that evaluated the NeoBase kit in parallel to the predicate device (identical specimens were analyzed as paired samples by both methods). The sample set consisted of 9416 random neonatal samples, 104 samples from with true positive diagnoses, and 320 artificially enriched dried blood spots. Clinical correlation was established by assessing whether or not the methods were concordant in determining the paired samples to have analyte concentration values above or below their corresponding cutoffs. Examination on the number of concordant pairs for $\cdot$ each analyte (cases in which both methods agreed) provided the percent agreements shown in Table 5.11.

Table 5.11: Percent agreement in clinical determinations by both methods (all samples)   

<table><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Total # ofObservations</td><td rowspan=1 colspan=1>% Agreement</td><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Total # ofObservations</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>ALA</td><td rowspan=1 colspan=1>2559</td><td rowspan=1 colspan=1>99.7%</td><td rowspan=1 colspan=1>C14</td><td rowspan=1 colspan=1>9813</td><td rowspan=1 colspan=1>99.9%</td></tr><tr><td rowspan=1 colspan=1>ARG</td><td rowspan=1 colspan=1>2564</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>C16</td><td rowspan=1 colspan=1>9803</td><td rowspan=1 colspan=1>99.9%</td></tr><tr><td rowspan=1 colspan=1>CIT</td><td rowspan=1 colspan=1>9805</td><td rowspan=1 colspan=1>99.8%</td><td rowspan=1 colspan=1>C18#</td><td rowspan=1 colspan=1>9781</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>GLYR</td><td rowspan=1 colspan=1>2474</td><td rowspan=1 colspan=1>99.8%</td><td rowspan=1 colspan=1>C4-OH/C3DC</td><td rowspan=1 colspan=1>2564</td><td rowspan=1 colspan=1>99.5%</td></tr><tr><td rowspan=1 colspan=1>LEU</td><td rowspan=1 colspan=1>9771</td><td rowspan=1 colspan=1>99.6%</td><td rowspan=1 colspan=1>C5:1 </td><td rowspan=1 colspan=1>9840</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>MET</td><td rowspan=1 colspan=1>9808</td><td rowspan=1 colspan=1>99.7%</td><td rowspan=1 colspan=1>C5-OH/C4DC*</td><td rowspan=1 colspan=1>7276</td><td rowspan=1 colspan=1>98.4%</td></tr><tr><td rowspan=1 colspan=1>ORN</td><td rowspan=1 colspan=1>2554</td><td rowspan=1 colspan=1>99.7%</td><td rowspan=1 colspan=1>C6DCM</td><td rowspan=1 colspan=1>9840</td><td rowspan=1 colspan=1>99.1%</td></tr><tr><td rowspan=1 colspan=1>PHE</td><td rowspan=1 colspan=1>9749</td><td rowspan=1 colspan=1>99.8%</td><td rowspan=1 colspan=1>C10:1</td><td rowspan=1 colspan=1>9840</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>TYR</td><td rowspan=1 colspan=1>9803</td><td rowspan=1 colspan=1>99.9%</td><td rowspan=1 colspan=1>C121</td><td rowspan=1 colspan=1>2564</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>VAL</td><td rowspan=1 colspan=1>9745</td><td rowspan=1 colspan=1>99.5%</td><td rowspan=1 colspan=1>C14:1</td><td rowspan=1 colspan=1>9840</td><td rowspan=1 colspan=1>99.9%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>9461</td><td rowspan=1 colspan=1>99.9%</td><td rowspan=1 colspan=1>C14:2</td><td rowspan=1 colspan=1>2564</td><td rowspan=1 colspan=1>99.9%</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>9808</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>C14-OH</td><td rowspan=1 colspan=1>2564</td><td rowspan=1 colspan=1>99.9%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>9781</td><td rowspan=1 colspan=1>99.9%</td><td rowspan=1 colspan=1>C16:1</td><td rowspan=1 colspan=1>2564</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>2559</td><td rowspan=1 colspan=1>99.9%</td><td rowspan=1 colspan=1>C16:1-OH</td><td rowspan=1 colspan=1>9840</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>C5</td><td rowspan=1 colspan=1>9809</td><td rowspan=1 colspan=1>99.6%</td><td rowspan=1 colspan=1>C16-OH</td><td rowspan=1 colspan=1>9840</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>C5DCO</td><td rowspan=1 colspan=1>9840</td><td rowspan=1 colspan=1>97.2%</td><td rowspan=1 colspan=1>C18:17</td><td rowspan=1 colspan=1>9840</td><td rowspan=1 colspan=1>99.0%</td></tr><tr><td rowspan=1 colspan=1>C6</td><td rowspan=1 colspan=1>9840</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>C18:1-OH</td><td rowspan=1 colspan=1>9840</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>C8</td><td rowspan=1 colspan=1>9840</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>C18:2</td><td rowspan=1 colspan=1>2564</td><td rowspan=1 colspan=1>99.9%</td></tr><tr><td rowspan=1 colspan=1>C10</td><td rowspan=1 colspan=1>9840</td><td rowspan=1 colspan=1>99.9%</td><td rowspan=1 colspan=1>C18-OH</td><td rowspan=1 colspan=1>9840</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>C12</td><td rowspan=1 colspan=1>2559</td><td rowspan=1 colspan=1>99.9%</td><td rowspan=1 colspan=3></td></tr></table>

\*Only one of the two sites measured the indicated analytes. eal seatis ssia  pla ctols  The seati removed from the analysis and thus the lesser number of observations vs. the 9840 total.

# COMPARISON OF TRUE POSITIVE SAMPLE RESULTS BETWEEN ASSAYS

In addition to the 104 true positive samples analyzed at the newborn screening sites, PerkinElmer R&D analyzed four Tyrosinemia Type I samples in parallel with both methods. Two of the 4 samples were acquired from the same subject approximately 14 days apart. The results for all true positive samples are summarized in Table 5.12

Table 5.12: Summary of the analysis of true Positive samples by the NeoBase and NeoGram assays. Disorders, along with number of corresponding true positive samples analyzed and detected are shown. N=108   

<table><tr><td colspan="1" rowspan="2">DisorderAbbreviation</td><td colspan="1" rowspan="2">Disorder Full name</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="2">DetectedDetectedbyNeoBasePredicateStudyStudy</td><td colspan="1" rowspan="2">DetectedDetectedbyNeoBasePredicateStudyStudy</td></tr><tr><td colspan="1" rowspan="1">NumberAnalyzed</td></tr><tr><td colspan="1" rowspan="1">3MCC</td><td colspan="1" rowspan="1">3-Methylcrotonyl-CoA Carboxylase Deficiency</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">9</td></tr><tr><td colspan="1" rowspan="1">CUD</td><td colspan="1" rowspan="1">Carnitine Uptake Defect</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">10</td></tr><tr><td colspan="1" rowspan="1">CTD</td><td colspan="1" rowspan="1">Carnitine Transporter Defect</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">CPT-1</td><td colspan="1" rowspan="1">Carnitine Palmitoyltransferase I Deficiency</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="2">GA-1</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="1" rowspan="1">Glutaric acidemia, type 1</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">9</td></tr><tr><td colspan="1" rowspan="1">HCY</td><td colspan="1" rowspan="1">Homocystinuria</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">7</td></tr><tr><td colspan="1" rowspan="1">IVA</td><td colspan="1" rowspan="1">Isovaleric acidemia</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">9</td></tr><tr><td colspan="1" rowspan="1">2MBDD</td><td colspan="1" rowspan="1">2-Methylbutyryl-CoA Dehydrogenase Deficiency</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">MCAD</td><td colspan="1" rowspan="1">Medium-Chain Acyl-CoA Dehydrogenase Deficiency</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">16</td></tr><tr><td colspan="1" rowspan="1">MCD</td><td colspan="1" rowspan="1">Multiple CoA Carboxylase Deficiency</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">3</td></tr><tr><td colspan="1" rowspan="1">MMA</td><td colspan="1" rowspan="1">MethyImalonic Aciduria</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">2</td></tr><tr><td colspan="1" rowspan="1">PPA</td><td colspan="1" rowspan="1">Propionic Acidemia</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">3</td></tr><tr><td colspan="1" rowspan="1">MSUD</td><td colspan="1" rowspan="1">Maple Syrup Urine Disease</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">2</td></tr><tr><td colspan="1" rowspan="1">SCAD</td><td colspan="1" rowspan="1">Short-Chain Acyl-CoA Dehydrogenase Deficiency</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">PKU</td><td colspan="1" rowspan="1">Phenylketonuria</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">12</td></tr><tr><td colspan="1" rowspan="1">CPT-2</td><td colspan="1" rowspan="1">Carnitine Palmitoyltransferase Il Deficiency</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">LCHAD</td><td colspan="1" rowspan="1">Long-Chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">5</td></tr><tr><td colspan="1" rowspan="1">VLCAD</td><td colspan="1" rowspan="1">Very Long-Chain Acyl-CoA Dehydrogenase Deficiency</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">10</td></tr><tr><td colspan="1" rowspan="1">VLCHAD</td><td colspan="1" rowspan="1">Very Long-Chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1"> TYR 1</td><td colspan="1" rowspan="1">Tyrosinemia Type 1</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">0</td></tr></table>

The data presented in Table 5.12 indicate that with the exception of Tyrosinemia Type 1, the NeoBase assay is just as sensitive as the predicate NeoGram assay in detecting the true positive samples. The two samples that neither of the two assays were able to 'detect based on the study cutoffs were a CPT-2 and a VLCAD case. The CPT-2 sample had been in storage for over three years and the VLCAD sample had been stored at room temperature for over one year. As a result, it is very likely that the acylcarnitine analytes in these samples had experienced a significant degree of decay during that period of time and thus causing the corresponding analytes to be below the study cutoffs.

One significant difference between the NeoBase and the NeoGram assays is the fact that the NeoBase assay enables the measurement and detection of succinylacetone (SA), the primary marker for Tyrosinemia Type I. The results of the analysis of four Tyrosinemia Type I true positive samples are presented in Table 5.13.

Table 5.13: SA and Tyr results for four true positives Tyrosinemia Type I samples. Results are shown in uM quantities.   

<table><tr><td rowspan=2 colspan=1>Site</td><td rowspan=1 colspan=1>Assay</td><td rowspan=1 colspan=2>NeoBase</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Marker</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>Tyr</td><td rowspan=1 colspan=1>Tyr</td></tr><tr><td rowspan=2 colspan=1>Patient 1</td><td rowspan=1 colspan=1>Sample1 (25 hours of age)</td><td rowspan=1 colspan=1>4.42</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Sample2_(15 days of age)</td><td rowspan=1 colspan=1>5.73</td><td rowspan=1 colspan=1>232</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Patient 2</td><td rowspan=1 colspan=1>Sample1</td><td rowspan=1 colspan=1>4.19</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>135</td></tr><tr><td rowspan=1 colspan=1>Patient 3</td><td rowspan=1 colspan=1>Sample2</td><td rowspan=1 colspan=1>4.46</td><td rowspan=1 colspan=1>227</td><td rowspan=1 colspan=1>247</td></tr></table>

From the data presented in Table 5.13 it is evident that when patients are afflicted with Tyrosinemia Type l, their blood contains highly elevated levels of succinylacetone. However, elevated levels of Tyrosine are not always associated with this disorder. In the four cases presented in table 5.13, all four SA measurements are above the corresponding cutoff of $> 2 \mu N$ However, all available Tyrosine measurements are below cutoffs $( < 3 0 0 | \mathsf { \ u { M } } )$ Such striking results indicate that inclusion of succinylacetone in the panel provides improved specificity and sensitivity in the detection of Tyrosinemia type I.

Finally, the established performance characteristics and method comparison at the analytical and clinical levels show that the Neo Base Non-derivatized MSMS kit is substantial equivalent to the predicate device.

PerkinElmer Inc.   
c/o Ms. Kay A. Taylor   
Senior Manager Regulatory Affairs Wallac Oy   
8275 Carloway Road   
Indianapolis, IN 46236

# JUL - 9 2009

Re: k083130 Trade Name: NeoBase Non-Derivatized MSMS Kit Regulation Number: 21 CFR $\ S 8 6 2 . 1 0 5 5$ EY Regulation Name: Newborn screening test system for amino acids, free carnitine; and acylcarnitines using tandem mass spectrometry. Regulatory Class: Class II Product Codes: NQL Dated: June 10, 2009 Received: June 11, 2009

Dear Ms. Taylor:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have eterie the devi is stantiy equivalen or the icatios orue tatenheence to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act.The general controls provisions f the Act includ requrements or annual rgistration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

I yur devic s cassee aboveinto either class  Specil Control)or classII MA), it y e subject t suc aditinal conrols.Exising majorregulations affecting your device can be foundin Tit, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with otherrequirements of theAct or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or ( 301 ) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

GC.H

Courtney C. Harper, Ph.D.   
Acting Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known): k083130

# Device Name: NeoBase Non-derivatized MSMS kit

Indications For Use:

The NeoBase Non-derivatized MSMS reagent kit is intended for the measurement and evaluation of amino acids, succinylacetone, free-carnitine, and acylcarnitine concentrations from newborn heel prick blood samples dried on filter paper.

Quantitative analysis of these analytes (Table 1) and their relationship with each other is intended to provide analyte concentration profiles that may aid in screening newborns for metabolic disorders.

Table 1. Analytes measured by the NeoBase Non-derivatized MSMS Kit.   

<table><tr><td rowspan=1 colspan=1>ANALYTE NAME</td><td rowspan=1 colspan=1>ABBREVIATION</td></tr><tr><td rowspan=1 colspan=2>Amino acids</td></tr><tr><td rowspan=1 colspan=1>Alanine</td><td rowspan=1 colspan=1>Ala</td></tr><tr><td rowspan=1 colspan=1>Arginine</td><td rowspan=1 colspan=1>Arg</td></tr><tr><td rowspan=1 colspan=1>Citrulline</td><td rowspan=1 colspan=1>Cit</td></tr><tr><td rowspan=1 colspan=1>Glycine</td><td rowspan=1 colspan=1>Gly</td></tr><tr><td rowspan=1 colspan=1>Leucine/Isoleucine/Hydroxyproline*</td><td rowspan=1 colspan=1>Leu/lle/Pro-OH</td></tr><tr><td rowspan=1 colspan=1>Methionine</td><td rowspan=1 colspan=1>Met</td></tr><tr><td rowspan=1 colspan=1>Ornithine</td><td rowspan=1 colspan=1>Orn</td></tr><tr><td rowspan=1 colspan=1>Phenylalanine</td><td rowspan=1 colspan=1>Phe</td></tr><tr><td rowspan=1 colspan=1>Proline</td><td rowspan=1 colspan=1>Pro</td></tr></table>

Prescription Use XX AND/OR Over-The-Counter Use (Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/dfd43c3e323094753a43acf644a2b822dfb0898421e45605217a07d284693919.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

<table><tr><td rowspan=1 colspan=1>ANALYTE NAME</td><td rowspan=1 colspan=1>ABBREVIATION</td></tr><tr><td rowspan=1 colspan=1>Carnitines</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Acetylcarnitine</td><td rowspan=1 colspan=1>C2</td></tr><tr><td rowspan=1 colspan=1>Propionylcarnitine</td><td rowspan=1 colspan=1>C3</td></tr><tr><td rowspan=1 colspan=1>Malonylcarnitine / 3-Hydroxy-butyrylcarnitine*</td><td rowspan=1 colspan=1>C3DC/C4OH</td></tr><tr><td rowspan=1 colspan=1>Butyrylcarnitine</td><td rowspan=1 colspan=1>C4</td></tr><tr><td rowspan=1 colspan=1>Methylmalonyl / 3-Hydroxy-isovalerylcarnitine*</td><td rowspan=1 colspan=1>C4DC/C5OH</td></tr><tr><td rowspan=1 colspan=1>Isovalerylcarnitine</td><td rowspan=1 colspan=1>C5</td></tr><tr><td rowspan=1 colspan=1>Tiglylcarnitine</td><td rowspan=1 colspan=1>C5:1</td></tr><tr><td rowspan=1 colspan=1>Glutarylcarnitine / 3-Hydroxy-hexanoylcarnitine*</td><td rowspan=1 colspan=1>C5DC/C6OH</td></tr><tr><td rowspan=1 colspan=1>Hexanoylcarnitine</td><td rowspan=1 colspan=1>C6</td></tr><tr><td rowspan=1 colspan=1>Adipylcarnitine</td><td rowspan=1 colspan=1>C6DC</td></tr><tr><td rowspan=1 colspan=1>Octanoylcarnitine</td><td rowspan=1 colspan=1>C8</td></tr><tr><td rowspan=1 colspan=1>Octenoylcarnitine</td><td rowspan=1 colspan=1>C8:1</td></tr><tr><td rowspan=1 colspan=1>Decanoylcarnitine</td><td rowspan=1 colspan=1>C10</td></tr><tr><td rowspan=1 colspan=1>Decenoylcarnitine</td><td rowspan=1 colspan=1>C10:1</td></tr><tr><td rowspan=1 colspan=1>Decadienoylcarnitine</td><td rowspan=1 colspan=1>C10:2</td></tr><tr><td rowspan=1 colspan=1>Dodecanoylcarnitine</td><td rowspan=1 colspan=1>C12</td></tr><tr><td rowspan=1 colspan=1>Dodecenoylcarnitine</td><td rowspan=1 colspan=1>C12:1</td></tr><tr><td rowspan=1 colspan=1>TetradecanoyIcarnitine (Myristoyicarnitine)</td><td rowspan=1 colspan=1>C14</td></tr><tr><td rowspan=1 colspan=1>Tetradecenoylcarnitine</td><td rowspan=1 colspan=1>C14:1</td></tr><tr><td rowspan=1 colspan=1>Tetradecadienoylcarnitine</td><td rowspan=1 colspan=1>C14:2</td></tr><tr><td rowspan=1 colspan=1>3-Hydroxy-tetradecanoylcarnitine</td><td rowspan=1 colspan=1>C140H</td></tr><tr><td rowspan=1 colspan=1>Hexadecanoylcarnitine (palmitoylcarnitine)</td><td rowspan=1 colspan=1>C16</td></tr><tr><td rowspan=1 colspan=1>Hexadecenoylcarnitine</td><td rowspan=1 colspan=1>C16:1</td></tr><tr><td rowspan=1 colspan=1>3-Hydroxy-hexadecanoylcarnitine</td><td rowspan=1 colspan=1>C160H</td></tr><tr><td rowspan=1 colspan=1>3-Hydroxy-hexadecenoylcarnitine</td><td rowspan=1 colspan=1>C16:10H</td></tr><tr><td rowspan=1 colspan=1>Octadecanoylcarnitine (Stearoylcarnitine)</td><td rowspan=1 colspan=1>C18</td></tr><tr><td rowspan=1 colspan=1>Octadecenoylcarnitine (Oleylcarnitine)</td><td rowspan=1 colspan=1>C18:1</td></tr><tr><td rowspan=1 colspan=1>Octadecadienoylcarnitine (Linoleylcarnitine)</td><td rowspan=1 colspan=1>C18:2</td></tr><tr><td rowspan=1 colspan=1>3-Hydroxy-octadecanoyicarnitine</td><td rowspan=1 colspan=1>C180H</td></tr><tr><td rowspan=1 colspan=1>3-Hydroxy-octadecenoylcarnitine</td><td rowspan=1 colspan=1>C18:10H</td></tr><tr><td rowspan=1 colspan=1>Ketones</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Succinylacetone</td><td rowspan=1 colspan=1>SA</td></tr></table>

Analytesn thee rows are ithesomersorsobars nd cannot e distinguished inhe tndm mass spectrometry experiment.

Prescription Use XX AND/OR Over-The-Counter Use (Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/a4b46e769409371968154b6c36e4472c69de61a8c43214e4fdf8dd26616151a6.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety